Reported about 23 hours ago
Recursion Pharmaceuticals, a clinical-stage biotech utilizing AI for drug discovery, shows potential for significant growth, especially following its merger with Exscientia. However, the company is years away from bringing a drug to market and faces financial challenges and competition from larger biotech firms. While its promising drug candidates could revolutionize treatment, the lack of immediate profitability raises caution for investors considering its stock.
Source: YAHOO